A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in
patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior
therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy)
and who are indicated for treatment per IWCLL2018.